Riluzole combination therapy for moderate-to-severe major depressive disorder: A randomized, double-blind, placebo-controlled trial

Journal of Psychiatric Research
Elaheh SalardiniShahin Akhondzadeh

Abstract

Recent evidences suggest that glutamatergic dysregulation implicated in neural plasticity and cellular resilience may contribute to the pathophysiology of Major Depressive Disorder (MDD). Riluzole, which exerts its effect by targeting glutamate neurotransmission, has shown antidepressant effect in recent preclinical, observational and open label studies. This study aimed to assess the efficacy and tolerability of riluzole in patients with MDD. Sixty-four inpatients with diagnosis of moderate to severe major depressive disorder participated in a parallel, randomized, controlled trial, and sixty patients underwent 6 weeks treatment with either riluzole (50 mg/bid) plus citalopram (40 mg/day) or placebo plus citalopram (40 mg/day). All participants were inpatients for the whole duration of the study. Patients were assessed using Hamilton depression rating scale (HDRS) at baseline and weeks 2, 4 and 6. The primary outcome measure was to assess the efficacy of riluzole compared to placebo in improving the depressive symptoms. General linear model repeated measures demonstrated significant effect for time × treatment interaction on HDRS [F (1.86, 107.82) = 8.63, p < 0.001]. Significantly greater improvement was observed in HDRS score...Continue Reading

References

Feb 1, 1960·Journal of Neurology, Neurosurgery, and Psychiatry·M HAMILTON
Dec 20, 2003·Annals of the New York Academy of Sciences·Carlos A ZarateHusseini K Manji
Jan 2, 2004·The American Journal of Psychiatry·Carlos A ZarateHusseini K Manji
Mar 31, 2004·Cellular and Molecular Neurobiology·Marcos Emílio dos Santos FrizzoDiogo Onofre Souza
Oct 30, 2004·The American Journal of Psychiatry·Gerard SanacoraJohn H Krystal
Aug 29, 2006·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Jing DuHusseini K Manji
Jun 19, 2007·Biological Psychiatry·Kenji HashimotoMasaomi Iyo
Aug 14, 2008·CNS Drugs·Christopher PittengerGerard Sanacora
Aug 30, 2008·Expert Opinion on Drug Metabolism & Toxicology·Carlos A Zarate, Husseini K Manji
Apr 21, 2009·Biochemical Pharmacology·Gerald W Valentine, Gerard Sanacora
May 28, 2009·The Neuroscientist : a Review Journal Bringing Neurobiology, Neurology and Psychiatry·Rodrigo Machado-VieiraCarlos A Zarate
Nov 10, 2009·Biological Psychiatry·Marije aan het RotSanjay J Mathew
Dec 4, 2009·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Brian P BrennanDost Ongür
Jan 22, 2010·CNS Drugs·Richard C SheltonSara A Corya
Sep 10, 2010·Harvard Review of Psychiatry·Carlos ZarateGiacomo Salvadore
Feb 3, 2012·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Lobna IbrahimCarlos A Zarate
May 3, 2012·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Khatereh SepanjniaShahin Akhondzadeh
Jun 9, 2012·The International Journal of Neuropsychopharmacology·Wallace C DuncanCarlos A Zarate
Jul 5, 2013·Journal of Pharmacological Sciences·Sachie Sasaki-HamadaJun-Ichiro Oka
Aug 27, 2013·Neuropsychiatric Disease and Treatment·Kyle Ab LapidusJames W Murrough
Nov 28, 2013·Pharmaceuticals·Zeynep Ates-Alagoz, Adeboye Adejare
Oct 16, 2015·International Clinical Psychopharmacology·Hamid Emadi-KouchakShahin Akhondzadeh

❮ Previous
Next ❯

Citations

Mar 21, 2017·Glia·Qian WangTian-Ming Gao
Mar 25, 2017·Journal of Clinical Psychopharmacology·Lawrence T ParkCarlos A Zarate
Jan 14, 2017·Clinical Neuropharmacology·Mahtab Roohi-AziziShahin Akhondzadeh
May 30, 2017·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Sanjay J MathewGerard Sanacora
May 23, 2018·Psychotherapy and Psychosomatics·Steven L Dubovsky
Dec 12, 2018·Journal of Psychopharmacology·Mohammad-Hadi FarahzadiShahin Akhondzadeh
Jan 19, 2017·Reviews in the Neurosciences·Anton S TsybkoNina K Popova
Oct 11, 2017·Annual Review of Pharmacology and Toxicology·Madeline L PfauScott J Russo
Oct 27, 2016·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Ebrahim HaroonGerard Sanacora
Feb 6, 2019·Advances in Pharmacological Sciences·Mervin Chávez-CastilloJoselyn Rojas-Quintero
Nov 4, 2020·Expert Opinion on Therapeutic Targets·Panek MałgorzataPilc Andrzej
Mar 17, 2021·European Journal of Pharmacology·David O Pacheco-RojasTania Ferrer

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.